News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Novartis AG Reports $2.28 Billion in Q3 Earnings
October 21, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 21 (Reuters) - Switzerland's Novartis AG (NOVN.VX) posted forecast-beating quarterly results as its newest drugs sold well, strengthening its position in the battle for a full takeover of U.S. eyecare group Alcon Inc (ACL.N).
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
Novartis
MORE ON THIS TOPIC
Layoff Tracker
Takeda cuts 4,500, Novartis lays off biomedical research staff
May 15, 2026
·
54 min read
·
BioSpace Editorial Staff
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
May 15, 2026
·
2 min read
·
Gabrielle Masson
Manufacturing
Sun Pharma recalls cancer drug after finding glass particles in some vials
May 15, 2026
·
2 min read
·
Nick Paul Taylor
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
·
3 min read
·
Annalee Armstrong
